New York 2025-2026 Regular Session

New York Senate Bill S02383

Introduced
1/16/25  
Refer
1/16/25  

Caption

Relates to the classification of the drug xylazine as a schedule I controlled substance, and to the criminal sale and possession of xylazine or preparations, compounds, mixtures or substances containing xylazine.

Companion Bills

No companion bills found.

Previously Filed As

NY HB1881

Adds xylazine to the list of Schedule III controlled substances

NY SB1724

Makes xylazine a Schedule III controlled substance

NY HB417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

NY A864

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

NY S2036

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

NY SB00749

An Act Classifying Xylazine As A Schedule Iv Controlled Substance.

NY HB0077

CONTROLLED SUB-XYLAZINE

NY SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.

NY SB465

Classifying xylazine as a schedule III controlled drug.

NY LD771

An Act to Include Possession of Compounds, Mixtures or Substances Containing a Detectable Amount of Certain Scheduled Drugs to Prove the Offense of Unlawful Trafficking of Scheduled Drugs

Similar Bills

CA AB1990

Pharmacy Law: compounded medications: consumer protection.

CA SB6

An act to amend Sections 11014.

CA SB1377

Immunizations: medical exemptions.

NY S09852

Provides that when a drug is designated or rescheduled by the federal government, it shall be deemed scheduled under NYS law automatically, without further action by the commissioner.

TN HB1112

AN ACT to amend Tennessee Code Annotated, Title 58, Chapter 2 and Title 68, Chapter 201, relative to weather modification.

TN SB1033

AN ACT to amend Tennessee Code Annotated, Title 58, Chapter 2 and Title 68, Chapter 201, relative to weather modification.

IN SB0282

Compounding drugs; registration of medical spas.

MO SB1724

Makes xylazine a Schedule III controlled substance